Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs D Wave Quantum Inc (QBTS) Price & Performance

Heron Therapeutics IncTrade
D Wave Quantum IncTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs D Wave Quantum Inc — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while D Wave Quantum Inc trades at $20.6 (market cap $7.53B). The key difference: D Wave Quantum Inc is far larger — about 122.5× Heron Therapeutics Inc's market cap, and D Wave Quantum Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXQBTS
Market Cap
$61.47M$7.53B
Sector
HealthTechnology
52-Week High
$1.49$44.78
52-Week Low
$0.32$12.98
Enterprise Value
$168.21M$7.04B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.

The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.

D Wave Quantum Inc

QBTS trades at $20.55, up 1.78% today, with a bearish technical signal despite 100% analyst buy ratings. The stock shows extreme valuation with a P/S of 583.84 and negative profitability, including a net income margin of -2,001.59% for 2026. Recent Q2 2026 earnings missed revenue and EPS estimates, though bookings surged 1,120%, highlighting growth potential amid financial strain. Cash flow trends indicate heavy investment outlays, with net cash flow turning negative in 2026.

Outlook remains speculative; the consensus price target of $38.29 offers significant upside, but high execution risks persist. Investors face volatility from unproven commercial scaling, reliance on financing, and competitive quantum computing pressures. The stock's appeal hinges on future revenue conversion from bookings, making it suitable for risk-tolerant investors betting on long-term quantum adoption.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About D Wave Quantum Inc

D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.

Read more on QBTS